| scholarly article | Q13442814 |
| P50 | author | Bruno Pereira | Q38523070 |
| Marion Couderc | Q82150982 | ||
| P2093 | author name string | Jean-Jacques Dubost | |
| Martin Soubrier | |||
| Sylvain Mathieu | |||
| Anne Tournadre | |||
| Baptiste Glace | |||
| P2860 | cites work | The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis | Q27860872 |
| Expert consensus document on arterial stiffness: methodological issues and clinical applications | Q33999785 | ||
| Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: 'establishing normal and reference values' | Q34166955 | ||
| Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity | Q34238357 | ||
| Reproducibility of pulse wave velocity and augmentation index measured by pulse wave analysis. | Q34487274 | ||
| The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis | Q35864053 | ||
| Increased lipid levels but unchanged atherogenic index in rheumatoid arthritis patients treated with biologic disease modifying antirheumatic drugs: published experience. | Q37552099 | ||
| Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies. | Q37583248 | ||
| Systematic review and meta‐analysis: Anti–tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis | Q37801353 | ||
| Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives | Q37812524 | ||
| Clinical safety of tocilizumab in rheumatoid arthritis | Q37814417 | ||
| Vascular function and morphology in rheumatoid arthritis: a systematic review | Q37934239 | ||
| Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: a systematic review with meta-analysis | Q37977885 | ||
| The effect of tumor necrosis factor-α antagonists on arterial stiffness in rheumatoid arthritis: a literature review | Q37999872 | ||
| Tocilizumab monotherapy reduces arterial stiffness as effectively as etanercept or adalimumab monotherapy in rheumatoid arthritis: an open-label randomized controlled trial | Q42611547 | ||
| Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis | Q43049221 | ||
| The effect of TNF-alpha blocking therapy on lipid levels in rheumatoid arthritis: a meta-analysis | Q44882366 | ||
| Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis | Q45251969 | ||
| Effects of rituximab treatment on endothelial dysfunction, carotid atherosclerosis, and lipid profile in rheumatoid arthritis | Q46075758 | ||
| Effects of repeated infliximab therapy on serum lipid profile in patients with refractory rheumatoid arthritis | Q46714949 | ||
| Effects of anti-tumor necrosis factor therapy on lipid profile in patients with rheumatoid arthritis | Q46987065 | ||
| ??? | Q56899447 | ||
| C-reactive protein is released in the coronary circulation and causes endothelial dysfunction in patients with acute coronary syndromes. | Q54357051 | ||
| Conversion towards an atherogenic lipid profile in rheumatoid arthritis patients during long‐term infliximab therapy | Q57819586 | ||
| A pilot study of endothelial dysfunction and aortic stiffness after interleukin-6 receptor inhibition in rheumatoid arthritis | Q60593768 | ||
| Effects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis | Q60809264 | ||
| Screening for atherosclerosis in patients with rheumatoid arthritis: comparison of two in vivo tests of vascular function | Q78794847 | ||
| Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis | Q82847957 | ||
| The effects of TNF-alpha blocking therapy on lipid levels in rheumatoid arthritis: a meta-analysis | Q82872642 | ||
| No significant change in arterial stiffness in RA after 6 months and 1 year of rituximab treatment | Q83430670 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | aorta | Q101004 |
| rheumatoid arthritis | Q187255 | ||
| P304 | page(s) | 259-264 | |
| P577 | publication date | 2013-12-02 | |
| P1433 | published in | Biologics: Targets and Therapy | Q4915042 |
| P1476 | title | Effects of 6 months of abatacept treatment on aortic stiffness in patients with rheumatoid arthritis | |
| P478 | volume | 7 |
| Q89970218 | Association between biologic disease modifying anti-rheumatic drugs and incident hypertension in patients with rheumatoid arthritis: Results from prospective nationwide KOBIO Registry |
| Q38737288 | Cardiac involvement in primary systemic vasculitis and potential drug therapies to reduce cardiovascular risk |
| Q88917533 | Cardiovascular Safety of Biologics and JAK Inhibitors in Patients with Rheumatoid Arthritis |
| Q38260198 | Cardiovascular risk and the use of biologic agents in rheumatoid arthritis |
| Q49788530 | Comparative Cardiovascular Risk of Abatacept and Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis With and Without Diabetes Mellitus: A Multidatabase Cohort Study |
| Q92628084 | Comparative effect of tumour necrosis factor inhibitors versus other biological agents on cardiovascular risk-associated biomarkers in patients with rheumatoid arthritis |
| Q41521795 | Disease duration of rheumatoid arthritis is a predictor of vascular stiffness: a cross-sectional study in patients without known cardiovascular comorbidities: A STROBE-compliant article |
| Q55172246 | Factors correlated with the improvement of endothelial dysfunction during Abatacept therapy in patients with rheumatoid arthritis. |
| Q89052358 | Remodeling of the HDL proteome with treatment response to abatacept or adalimumab in the AMPLE trial of patients with rheumatoid arthritis |
| Q46172380 | Review of Routine Laboratory Monitoring for Patients with Rheumatoid Arthritis Receiving Biologic or Nonbiologic DMARDs. |
| Q38794852 | Rheumatoid Arthritis Pharmacotherapies: Do They Have Anti-Atherosclerotic Activity? |
| Q35675593 | The Impact of Newer Biological Disease Modifying Anti-Rheumatic Drugs on Cardiovascular Risk Factors: A 12-Month Longitudinal Study in Rheumatoid Arthritis Patients Treated with Rituximab, Abatacept and Tociliziumab |
Search more.